• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Core Laboratories Inc.

    5/24/24 4:09:39 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy
    Get the next $CLB alert in real time by email
    S-8 1 clb-_s-8_2024.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 24, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    _______________________________________

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ________________________________________

    Core Laboratories Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

     

    98-1164194

    (State or other jurisdiction of incorporation)

     

    (I.R.S. Employer Identification No.)

     

    6316 Windfern Road,
    Houston, Texas 77040

    (713) 328-2673

    (Address of Principal Executive Offices)

     

    Core Laboratories Inc. 2024 Long Term Incentive Plan

    (as amended and restated effective as of May 8, 2024)

    (Full titles of the plans)

     

    Mark D. Tattoli

    Senior Vice President, Secretary and General Counsel

    Core Laboratories Inc.

    6316 Windfern Road

    Houston, Texas 77040

    (713) 328-2673

    (Name and address of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

     

     

     

     

     

     

     

    Large accelerated filer

     

    ☒

     

    Accelerated filer

     

    ☐

     

     

     

     

    Non-accelerated filer

     

    ☐

     

    Smaller reporting company

     

    ☐

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


    EXPLANATORY NOTE

    Core Laboratories Inc. (the “Registrant”), is filing this registration statement on Form S-8 (this “Registration Statement”) pursuant to General Instruction E of Form S-8 to register the offer and sale of an additional 1,100,000 shares of Common Stock that may be issued to employees under our employee equity incentive plan that will come from a combination of treasury shares and the issuance of new shares, as necessary, under the Plan. The additional 1,100,000 shares were approved by the Registrant’s shareholders at its 2024 annual shareholder meeting in connection with the amendment and restatement of the Plan, which was previously filed by Core Laboratories N.V., the predecessor issuer to the Registrant, and titled the “Core Laboratories N.V. 2020 Long-Term Incentive Plan.” Except as otherwise set forth below, the contents of the Registrant’s registration statements on Form S-8 relating to the Plan, which were previously filed with the Securities and Exchange Commission (the “Commission”) on August 19, 2020 (File No. 333-248137), May 8, 2019 (File No. 333-231277) and November 20, 2001 (File No. 333-73774), and the post-effective Amendment No. 1 to Form S-8 filed with the Commission on May 2, 2023 (File Nos. 333-248137, 333-231277 and 333-73774) are incorporated by reference into this Registration Statement as permitted by General Instruction E of Form S-8.

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    The Registrant will provide all participants in the Plan with the document(s) containing the information required by Part I of Form S-8, as specified in Rule 428(b)(1) promulgated by the Commission under the Securities Act. In accordance with Rule 428 of the Securities Act, the Registrant has not filed such document(s) with the Commission, but such document(s) (along with the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II hereof) shall constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. The Registrant shall maintain a file of such documents in accordance with the provisions of Rule 428(a)(2) of the Securities Act. Upon request, the Registrant shall furnish to the Commission or its staff a copy or copies of all of the documents included in such file.

     

     

     


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    The following exhibits are filed as part of this Amendment:

     

    Item Number

    Description

    4.1

    Core Laboratories Inc. Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-41695) filed with the Commission on May 1, 2023).

    4.2

    Core Laboratories Inc. Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-41695) filed with the Commission on May 1, 2023).

    4.3

    Core Laboratories Inc. 2024 Long Term Incentive Plan (as amended and restated effective as of May 8, 2024)(incorporated by reference to the Core Laboratories Inc. Proxy Statement filed with the Commission on March 19, 2024)(File No. 001-41695).

    5.1*

    Opinion of Vinson & Elkins LLP as to the legality of the securities being registered.

    23.1*

    Consent of KPMG LLP.

    23.2*

    Consent of Vinson & Elkins LLP (included in Exhibit 5.1).

    24.1*

    Powers of Attorney (included on the signature page herein).

    107.1*

    Filing Fee Table.

    * Filed herewith

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Houston, Texas, on May 24, 2024.

     

     

     

     

    CORE LABORATORIES INC.

     

     

    By:

     

    /s/ Christopher S. Hill

     

     

    Name:   Christopher S. Hill

     

     

    Title:    Chief Financial Officer

     

     

     

     

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark D. Tattoli as his or her true and lawful attorney-in-fact and agent, with full power of substitution for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully and to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or their or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    [Signatures on Next Page.]

     

     

     


    Pursuant to the requirements of the Securities Act, this Registration Statement and the above Power of Attorney have been signed below by the following persons in the capacities indicated on May 24, 2024.

     

     

     

     

    Name

     

    Position

     

     

    /s/ Lawrence Bruno

    Lawrence Bruno

     

    Chief Executive Officer, President, Chief Operating Officer and Chairman

    (Principal Executive Officer)

     

     

    /s/ Christopher S. Hill

    Christopher S. Hill

     

    Senior Vice President and Chief Financial Officer

    (Principal Financial Officer)

     

     

    /s/ Sow Hang Teo

    Sow Hang Teo

     

    Chief Accounting Officer

    (Principal Accounting Officer)

     

     

     

    /s/ Martha Z. Carnes

    Martha Z. Carnes

     

    Director

     

     

    /s/ Harvey Klingensmith

    Harvey Klingensmith

     

    Director

     

     

    /s/ Kwaku Temeng

    Kwaku Temeng

     

    Director

     

     

    /s/ Katherine A. Murray

    Katherine A. Murray

     

    Director

     

     

    /s/ Michael Straughen

    Michael Straughen

     

    Director

     

     

     

    /s/ Curtis Anastasio

     

    Director

    Curtis Anastasio

     

     

     

     

     

     

     

     


    SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT

    Pursuant to the Securities Act the undersigned, a duly authorized representative of the Registrant in the United States, has signed the Registration Statement in the City of Houston, State of Texas, on May 24, 2024.

     

     

     

     

    CORE LABORATORIES INC.

     

     

    By:

     

    /s/ Mark D. Tattoli

     

     

    Name:   Mark D. Tattoli

     

     

    Title:    Senior Vice President, Secretary and General Counsel

     

     

     

     

     


    Get the next $CLB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLB

    DatePrice TargetRatingAnalyst
    3/12/2025$15.00 → $16.00Sell → Neutral
    Citigroup
    6/30/2023$22.00 → $21.00Neutral → Sell
    Citigroup
    4/18/2023$21.50Neutral → Underperform
    BofA Securities
    1/9/2023Underperform → Neutral
    BofA Securities
    10/7/2022$24.00 → $17.00Sell → Neutral
    Citigroup
    9/26/2022$20.00Equal-Weight → Underweight
    Morgan Stanley
    4/18/2022$19.50 → $21.30Neutral → Underweight
    Piper Sandler
    1/18/2022$32.00 → $30.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Core Labs upgraded by Citigroup with a new price target

    Citigroup upgraded Core Labs from Sell to Neutral and set a new price target of $16.00 from $15.00 previously

    3/12/25 7:22:24 AM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    Core Labs downgraded by Citigroup with a new price target

    Citigroup downgraded Core Labs from Neutral to Sell and set a new price target of $21.00 from $22.00 previously

    6/30/23 7:19:53 AM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    Core Labs downgraded by BofA Securities with a new price target

    BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $21.50

    4/18/23 9:05:50 AM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    $CLB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

    FOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEARFOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER 11%, DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEARFOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.21, DOWN 4% SEQUENTIALLY AND YEAR-OVER-YEARFOURTH QUARTER FREE CASH FLOW OF $5.1 MILLIONNET DEBT REDUCED BY $1.2 MILLION; LEVERAGE RATIO IMPROVED TO 1.09COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR $5.7 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $526.5 MILLI

    2/4/26 5:15:00 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL

    HOUSTON, Jan. 5, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2025 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on February 5, 2026. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on February 4, 2026, and may be accessed through the Company's website at www.corelab.com/investors. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webc

    1/5/26 4:05:00 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    CORE LAB REPORTS THIRD QUARTER 2025 RESULTS

    REVENUE OF $134.5 MILLION, UP OVER 3% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $20.9 MILLION; EX-ITEMS, $16.6 MILLION, UP OVER 14% SEQUENTIALLY AND DOWN 9% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF OVER 12%, EXPANDED 120 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF 48%GAAP EPS OF $0.30; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY, AND DOWN 12% YEAR-OVER-YEARCOMPANY REPURCHASED 462,248 SHARES OF COMMON STOCK, A VALUE OF $5.0 MILLION FREE CASH FLOW OF $6.5 MILLIONNET DEBT REDUCED BY $3.4 MILLION; LEVERAGE RATIO IMPROVED TO 1.10 COMPANY ANNOUNCES Q3 2025 QUARTERLY DIVIDEND HOUSTON, Oct. 22, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core

    10/22/25 5:00:00 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    $CLB
    SEC Filings

    View All

    Core Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)

    2/4/26 4:58:29 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    Amendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.

    SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)

    11/14/25 3:42:50 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    Amendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.

    SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)

    11/14/25 11:18:40 AM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    $CLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Gen Counsel & Secretary Tattoli Mark Damian covered exercise/tax liability with 14,310 shares and converted options into 24,952 shares (SEC Form 4)

    4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)

    1/5/26 3:18:37 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    SVP Gresham Gwendolyn covered exercise/tax liability with 19,301 shares and converted options into 24,952 shares (SEC Form 4)

    4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)

    1/5/26 3:18:06 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    SVP & CFO Hill Christopher Scott covered exercise/tax liability with 32,152 shares and converted options into 61,417 shares (SEC Form 4)

    4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)

    1/5/26 3:17:09 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    $CLB
    Financials

    Live finance-specific insights

    View All

    CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

    FOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEARFOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER 11%, DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEARFOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.21, DOWN 4% SEQUENTIALLY AND YEAR-OVER-YEARFOURTH QUARTER FREE CASH FLOW OF $5.1 MILLIONNET DEBT REDUCED BY $1.2 MILLION; LEVERAGE RATIO IMPROVED TO 1.09COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR $5.7 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $526.5 MILLI

    2/4/26 5:15:00 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL

    HOUSTON, Jan. 5, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2025 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on February 5, 2026. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on February 4, 2026, and may be accessed through the Company's website at www.corelab.com/investors. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webc

    1/5/26 4:05:00 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    CORE LAB REPORTS THIRD QUARTER 2025 RESULTS

    REVENUE OF $134.5 MILLION, UP OVER 3% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $20.9 MILLION; EX-ITEMS, $16.6 MILLION, UP OVER 14% SEQUENTIALLY AND DOWN 9% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF OVER 12%, EXPANDED 120 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF 48%GAAP EPS OF $0.30; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY, AND DOWN 12% YEAR-OVER-YEARCOMPANY REPURCHASED 462,248 SHARES OF COMMON STOCK, A VALUE OF $5.0 MILLION FREE CASH FLOW OF $6.5 MILLIONNET DEBT REDUCED BY $3.4 MILLION; LEVERAGE RATIO IMPROVED TO 1.10 COMPANY ANNOUNCES Q3 2025 QUARTERLY DIVIDEND HOUSTON, Oct. 22, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core

    10/22/25 5:00:00 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    $CLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Core Laboratories Inc. (Amendment)

    SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)

    6/12/23 4:02:30 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    SEC Form SC 13G/A filed by Core Laboratories N.V. (Amendment)

    SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)

    2/14/23 4:08:12 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy

    SEC Form SC 13G/A filed by Core Laboratories N.V. (Amendment)

    SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)

    2/14/23 9:10:51 AM ET
    $CLB
    Oilfield Services/Equipment
    Energy